ARGX vs. GILD, MRNA, BIIB, BNTX, NBIX, TECH, QGEN, RGEN, PCVX, and RVMD
Should you be buying argenx stock or one of its competitors? The main competitors of argenx include Gilead Sciences (GILD), Moderna (MRNA), Biogen (BIIB), BioNTech (BNTX), Neurocrine Biosciences (NBIX), Bio-Techne (TECH), Qiagen (QGEN), Repligen (RGEN), Vaxcyte (PCVX), and Revolution Medicines (RVMD). These companies are all part of the "biological products, except diagnostic" industry.
argenx (NASDAQ:ARGX) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation, community ranking and media sentiment.
60.3% of argenx shares are owned by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are owned by institutional investors. 2.4% of argenx shares are owned by insiders. Comparatively, 0.2% of Gilead Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Gilead Sciences has higher revenue and earnings than argenx. argenx is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, Gilead Sciences had 14 more articles in the media than argenx. MarketBeat recorded 24 mentions for Gilead Sciences and 10 mentions for argenx. argenx's average media sentiment score of 1.05 beat Gilead Sciences' score of 0.32 indicating that argenx is being referred to more favorably in the media.
Gilead Sciences received 1847 more outperform votes than argenx when rated by MarketBeat users. Likewise, 77.37% of users gave Gilead Sciences an outperform vote while only 65.90% of users gave argenx an outperform vote.
argenx has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500.
argenx currently has a consensus price target of $520.68, suggesting a potential upside of 40.34%. Gilead Sciences has a consensus price target of $83.69, suggesting a potential upside of 30.21%. Given argenx's stronger consensus rating and higher probable upside, equities analysts clearly believe argenx is more favorable than Gilead Sciences.
Gilead Sciences has a net margin of 1.76% compared to argenx's net margin of -22.58%. Gilead Sciences' return on equity of 24.34% beat argenx's return on equity.
Summary
Gilead Sciences beats argenx on 11 of the 19 factors compared between the two stocks.
Get argenx News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARGX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ARGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
